Geode Capital Management
CGEM icon

Geode Capital Management’s Cullinan Oncology CGEM Stock Holding History

Geode Capital Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.4M Buy
1,368,268
+66,006
+5% +$848K ﹤0.01% 2007
2025
Q4 		$13.5M Buy
1,302,262
+6,942
+0.5% +$62.6K ﹤0.01% 2240
2025
Q3 		$7.68M Buy
1,295,320
+15,824
+1% +$116K ﹤0.01% 2566
2025
Q2 		$9.64M Buy
1,279,496
+37,679
+3% +$303K ﹤0.01% 2392
2025
Q1 		$9.4M Buy
1,241,817
+27,176
+2% +$261K ﹤0.01% 2330
2024
Q4 		$14.8M Buy
1,214,641
+6,220
+0.5% +$89.4K ﹤0.01% 2125
2024
Q3 		$20.2M Buy
1,208,421
+231,935
+24% +$4.11M ﹤0.01% 1969
2024
Q2 		$17M Buy
976,486
+299,156
+44% +$6.37M ﹤0.01% 2025
2024
Q1 		$11.5M Buy
677,330
+21,666
+3% +$335K ﹤0.01% 2243
2023
Q4 		$6.68M Buy
655,664
+64,841
+11% +$574K ﹤0.01% 2555
2023
Q3 		$5.35M Buy
590,823
+78,477
+15% +$817K ﹤0.01% 2601
2023
Q2 		$5.51M Sell
512,346
-25,477
-5% -$271K ﹤0.01% 2627
2023
Q1 		$5.5M Sell
537,823
-19,285
-3% -$213K ﹤0.01% 2596
2022
Q4 		$5.88M Buy
557,108
+15,588
+3% +$189K ﹤0.01% 2582
2022
Q3 		$6.94M Buy
541,520
+36,526
+7% +$492K ﹤0.01% 2484
2022
Q2 		$6.47M Buy
504,994
+62,453
+14% +$708K ﹤0.01% 2553
2022
Q1 		$4.63M Buy
442,541
+10,670
+2% +$144K ﹤0.01% 2837
2021
Q4 		$6.66M Buy
431,871
+10,633
+3% +$212K ﹤0.01% 2722
2021
Q3 		$9.51M Buy
421,238
+188,316
+81% +$5.04M ﹤0.01% 2479
2021
Q2 		$6M Buy
232,922
+12,655
+6% +$389K ﹤0.01% 2794
2021
Q1 		$9.18M Buy
+220,267
New +$8.94M ﹤0.01% 2417

Other funds holding CGEM

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Geode Capital Management's CGEM Position: Q1 2026 in Review

Geode Capital Management increased its Cullinan Oncology (CGEM) stake by 5.1% in Q1 2026, buying an estimated $848K and bringing the position to 1,368,268 shares worth $19.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2007.

Geode Capital Management first reported a position in CGEM in Q1 2021 and has held it in 21 quarters since. The position peaked at $20.2M in Q3 2024. 174 funds tracked by Wall St. Rank hold CGEM as of Q1 2026.

  • Geode Capital Management held 1,368,268 shares of Cullinan Oncology worth $19.4M as of Q1 2026.
  • Geode Capital Management bought 66,006 Cullinan Oncology shares in Q1 2026, an estimated $848K.
  • Cullinan Oncology made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #2007 holding.
  • Geode Capital Management first reported a position in Cullinan Oncology in Q1 2021 and has held it in 21 quarters since.
  • Geode Capital Management's Cullinan Oncology position peaked at $20.2M in Q3 2024.
  • 174 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.